July 15, 2025

Alkaloid known as 7-OH is not a lawful dietary supplement, food additive, or ingredient in any approved drug

 

The U.S. Food and Drug Administration today announced seven recent warning letters sent to companies for illegally marketing products containing 7-hydroxymitragynine, also known as 7-OH.1  This action reflects the Agency’s growing concern around novel potent opioid products being marketed to U.S. consumers and sold online and in smoke shops, gas stations, and corner stores. While 7-OH occurs naturally in trace amounts in kratom, the Agency’s letters focus on concentrated 7-OH products such as tablets, gummies, drink mixes, and shots, which may be dangerous. 

7-OH is not lawful in dietary supplements and cannot be lawfully added to conventional foods. Additionally, there are no FDA-approved drugs containing 7-OH, and it is illegal to market any drugs containing 7-OH. Consumers who use 7-OH products are exposing themselves to products that have not been proven safe or effective for any use.

The warning letters address the illegal marketing of products containing 7-OHExternal Link Disclaimer. These letters specifically focus on products containing 7-OH as an added ingredient or enhanced levels of 7-OH. Some products are adulterated conventional foods or dietary supplements because 7-OH does not meet the relevant safety standard. Others are unapproved new drugs with unproven claims such as relieving pain and managing anxiety.

The FDA issued warning letters to:

The letters requested that the recipients respond within 15 business days.

Contact us
Thank you for your interest in Garg Law PLLC.
Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.
If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.
Garg Law Global Icon

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.